Showing results (111-120 of 145) with videos related to

Sort By:
Pageof 15
Oncology|November 29, 2008
Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trialS Pignata, G Scambia, A Savarese, et al.
Cancer Chemotherapy and Pharmacology|May 19, 2010
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumorsF Caponigro, D Lorusso, G Fornari, et al.
ESMO Open|July 18, 2022
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?L Musacchio, C M Cicala, F Camarda, et al.
British Journal of Cancer|May 31, 2012
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patientsD Lorusso, G Scambia, G Amadio, et al.
British Journal of Cancer|May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) groupS Pignata, G Scambia, C Pisano, et al.
Biochemical Pharmacology|August 8, 2017
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoproteinE Erba, M Romano, M Gobbi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2012
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cellsShahriar Koochekpour, Sunipa Majumdar, Gissou Azabdaftari, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2021
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancerI Vergote, A González-Martín, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialD Lorusso, G Scambia, S Pignata, et al.
ESMO Open|April 9, 2022
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumorsS Ochsenreither, W M Fiedler, G D Conte, et al.
Pageof 15